HSP90 inhibitors can enhance the efficacy of other anticancer treatments, such as radiotherapy and chemotherapy, by directly downregulating the pathways associated with drug resistance mechanisms and indirectly enhancing anticancer activity by inhibiting multiple tumor survival/growth pathways. The gene discussed is HSP90AA1; the disease is neoplasm.